Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer | European Respiratory Society
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Mechanisms of osimertinib resistance and emerging treatment options - Lung Cancer
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Overview of probable resistance mechanisms in EGFR-TKI afatinib.... | Download Scientific Diagram
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer | Molecular Cancer Therapeutics
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
Figure 2 from Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. | Semantic Scholar
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer - Annals of Oncology
Afatinib/Cetuximab in EGFR TKI-Resistant NSCLC
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics | PNAS
HCC827 GR cells are resistant to gefitinib in vitro and show MET... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
![Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram](https://www.researchgate.net/publication/328978288/figure/fig2/AS:693427310178304@1542337362022/Mechanisms-of-acquired-resistance-to-osimertinib-32-36-EGFR-epidermal-growth-factor.png "Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram")
Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
Resistance mechanisms to osimertinib in EGFR -mutated non-small cell lung cancer | British Journal of Cancer
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Cells | Free Full-Text | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy | HTML
Frontiers | Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors | Oncology
